Medical Research

Finerenone Meets Primary Endpoint in a Phase III cardiovascular outcomes study, Bayer recently announced the positive results from its Phase III FINEARTS-HF study, which evaluated the efficacy and safety of finerenone in patients with heart failure with mildly reduced...